Hong Kong, China – On May 21, Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") gained the approval from Hong Kong Hospital Authority, allowing it to enter in Hong Kong public hospitals. It is the first drug-eluting stent of MicroPort® that was granted launch approval in Hong Kong.
Firehawk® is the result of eight years of research and development of MicroPort® and it is the world's first and only target-eluting stent ("TES"). It is a new-generation drug-eluting stent of MicroPort® for the treatment of coronary artery stenosis or occlusion after Firebird® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird®") and Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®"). Firehawk® adopts TES Technology platform, and its coating area is only 20% of the stent surface. Firehawk®'s drug is released over 90 days and its polymer is fully absorbed in nine months. Its average metal coverage rate is 14.0-16.1%. Firehawk® is the world's lowest drug dosage stent, with only 1/3 dosage versus similar products while achieving the same efficacy.
Firehawk®'s Hong Kong launch marks a milestone in its market development. With its outstanding performance, it is expected that Firehawk® will provide more ideal cardiovascular treatment for local patients and help enhance the communication between cardiologists from Hong Kong and the mainland as well.